Personal information

No personal information available

Activities

Collapse all

Works (12)

Depression and treatment with anti‐calcitonin gene related peptide (CGRP) (ligand or receptor) antibodies for migraine

European Journal of Neurology
2024-02 | Journal article
DOI: 10.1111/ene.16106
Contributors: Simone de Vries Lentsch; Britt W. H. van der Arend; Irene de Boer; Erik W. van Zwet; Antoinette MaassenVanDenBrink; Gisela M. Terwindt
Source: check_circle
Crossref

Both perimenstrual and nonperimenstrual migraine days respond to anti‐calcitonin gene‐related peptide (receptor) antibodies

European Journal of Neurology
2023-07 | Journal article
DOI: 10.1111/ene.15794
Contributors: Iris E. Verhagen; Simone de Vries Lentsch; Britt W. H. van der Arend; Saskia le Cessie; Antoinette MaassenVanDenBrink; Gisela M. Terwindt
Source: check_circle
Crossref

Visual hypersensitivity in patients treated with anti‐calcitonin gene–related peptide (receptor) monoclonal antibodies

Headache: The Journal of Head and Face Pain
2023-07 | Journal article
DOI: 10.1111/head.14531
Contributors: Simone de Vries Lentsch; Matthijs J. L. Perenboom; Johannes A. Carpay; Antoinette MaassenVanDenBrink; Gisela M. Terwindt
Source: check_circle
Crossref

Characterizing opioid use in a Dutch cohort with migraine

Cephalalgia
2023-05 | Journal article
DOI: 10.1177/03331024231174160
Contributors: Rein F van Welie; Floor C van Welie; Simone de Vries Lentsch; Albert Dahan; Monique van Velzen; Gisela M Terwindt
Source: check_circle
Crossref

Blood Pressure in Patients With Migraine Treated With Monoclonal Anti-CGRP (Receptor) Antibodies

Neurology
2022-10-25 | Journal article
DOI: 10.1212/WNL.0000000000201008
Contributors: Simone de Vries Lentsch; Britt W.H. van der Arend; Antoinette Maassen VanDenBrink; Gisela M. Terwindt
Source: check_circle
Crossref

Serum CGRP in migraine patients using erenumab as preventive treatment.

The journal of headache and pain
2022-09-12 | Journal article
DOI: 10.1186/s10194-022-01483-z
PMID: 36089587
PMC: PMC9464612
Contributors: Simone de Vries Lentsch; Garrelds IM; Danser AHJ; Terwindt GM; MaassenVanDenBrink A
Source: Self-asserted source
Simone de Vries Lentsch

CGRP-mediated trigeminovascular reactivity in migraine patients treated with erenumab

Journal of Neurology, Neurosurgery & Psychiatry
2022-08 | Journal article
DOI: 10.1136/jnnp-2021-327992
Contributors: Simone de Vries Lentsch; Linda Al-Hassany; Michel Dominique Ferrari; Gisela Marie Terwindt; Antoinette MaassenVanDenBrink
Source: check_circle
Crossref

Depressive symptoms during the different phases of a migraine attack: A prospective diary study

Journal of Affective Disorders
2022-01 | Journal article
DOI: 10.1016/j.jad.2021.10.046
Part of ISSN: 0165-0327
Source: Self-asserted source
Simone de Vries Lentsch

Treatment with the monoclonal calcitonin gene‐related peptide receptor antibody erenumab: A real‐life study

European Journal of Neurology
2021-12 | Journal article
DOI: 10.1111/ene.15075
Contributors: Simone de Vries Lentsch; Iris E. Verhagen; Thomas C. van den Hoek; Antoinette MaassenVanDenBrink; Gisela M. Terwindt
Source: check_circle
Crossref

E-diary use in clinical headache practice: A prospective observational study

Cephalalgia
2021-05-02 | Journal article
DOI: 10.1177/03331024211010306
Part of ISSN: 0333-1024
Part of ISSN: 1468-2982
Source: Self-asserted source
Simone de Vries Lentsch

Changing levels of sex hormones and calcitonin gene-related peptide (CGRP) during a woman’s life: Implications for the efficacy and safety of novel antimigraine medications

Maturitas
2021-03 | Journal article
DOI: 10.1016/j.maturitas.2020.12.012
Contributors: Simone de Vries Lentsch; Eloísa Rubio-Beltrán; Antoinette MaassenVanDenBrink
Source: check_circle
Crossref

Effect of lockdown during COVID-19 on migraine: A longitudinal cohort study.

Cephalalgia : an international journal of headache
2021-01-11 | Journal article
DOI: 10.1177/0333102420981739
PMID: 33430642
Source: Self-asserted source
Simone de Vries Lentsch
How many people are using ORCID?